Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Author:
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology
Reference39 articles.
1. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications;Chao;Curr Opin Immunol,2012
2. Monoclonal antibody against human ovarian tumor-associated antigens;Poels;J Natl Cancer Inst,1986
3. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells;Majeti;Cell,2009
4. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells;Kim;Leukemia.,2012
5. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma;Chao;Cell,2010
Cited by 200 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13
2. Breaking Boundaries: Immunotherapy for Myeloid Malignancies;Cancers;2024-08-06
3. Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth;Cancers;2024-08-06
4. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08
5. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3